Zymeworks (ZYME) Projected to Post Quarterly Earnings on Monday

Zymeworks (NASDAQ:ZYME) is anticipated to issue its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to announce earnings of $2.27 per share and revenue of $227.40 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Zymeworks (NASDAQ:ZYME) last released its earnings results on Friday, August 7th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). Zymeworks had a negative net margin of 405.31% and a negative return on equity of 72.30%. The company had revenue of $3.23 million during the quarter, compared to analysts’ expectations of $4.54 million. During the same quarter in the previous year, the firm posted $0.03 earnings per share. Zymeworks’s revenue for the quarter was down 90.6% compared to the same quarter last year. On average, analysts expect Zymeworks to post $1.32 EPS for the current fiscal year and $1.27 EPS for the next fiscal year.

Zymeworks Price Performance

Zymeworks stock opened at $28.61 on Monday. The firm has a market capitalization of $2.02 billion, a P/E ratio of -14.16 and a beta of 1.17. The firm has a fifty day moving average of $27.30 and a 200-day moving average of $25.20. Zymeworks has a 52-week low of $16.00 and a 52-week high of $31.34.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on ZYME shares. B. Riley Financial reissued a “buy” rating and issued a $44.00 price target (up from $40.00) on shares of Zymeworks in a report on Monday, August 10th. TD Cowen assumed coverage on shares of Zymeworks in a research report on Tuesday, September 29th. They set a “buy” rating and a $34.00 price target on the stock. Citizens Jmp restated a “market outperform” rating and set a $32.00 price objective on shares of Zymeworks in a research note on Wednesday, August 26th. Deutsche Bank Aktiengesellschaft set a $32.00 target price on Zymeworks in a research report on Wednesday, August 26th. Finally, HC Wainwright lifted their price target on Zymeworks from $51.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, August 26th. Twelve equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Zymeworks presently has an average rating of “Moderate Buy” and an average price target of $41.67.

Insider Activity at Zymeworks

In other news, EVP Adam Schayowitz sold 13,832 shares of Zymeworks stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $25.85, for a total value of $357,557.20. Following the completion of the transaction, the executive vice president directly owned 23,205 shares of the company’s stock, valued at approximately $599,849.25. This trade represents a 37.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 33.51% of the company’s stock.

About Zymeworks

Zymeworks Inc is a biopharmaceutical company focused on discovering, developing and commercializing multifunctional biotherapeutics for cancer and other serious diseases. The company is headquartered in Vancouver, British Columbia, and has historically operated internationally through research, development and collaboration activities.

Zymeworks’ technology platforms include Azymetric, which is designed to support the development of engineered antibody therapeutics, and ZymeLink, which enables the creation of antibody-drug conjugates and other targeted therapies.